| 摘要 |
PCT No. PCT/US92/07117 Sec. 371 Date Oct. 7, 1993 Sec. 102(e) Date Oct. 7, 1993 PCT Filed Aug. 21, 1992.A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24, N28 and N29 monoclonal antibodies are described which have been identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary cancers.
|
